Premium
Biodistribution of post‐therapeutic versus diagnostic 131 I‐MIBG scans in children with neuroblastoma
Author(s) -
Hickeson Marc P.,
Charron Martin,
Maris John M.,
Brophy Patricia,
Kang Tammy I.,
Zhuang Hongming,
Khan Jehanzeb,
Nevrotski Teresa
Publication year - 2004
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.10454
Subject(s) - medicine , biodistribution , neuroblastoma , nuclear medicine , scintigraphy , occult , radiology , pathology , in vivo , alternative medicine , microbiology and biotechnology , biology , genetics , cell culture
Background To evaluate the biodistribution of therapeutic 131 I‐metaiodobenzylguanidine (MIBG) and assess the sensitivity of diagnostic versus therapeutic 131 I‐MIBG scans to detect metastatic disease. Procedure This retrospective study included 44 diagnostic and post‐therapy scans (PTS) in 18 children with neuroblastoma treated with 131 I‐MIBG (2.0–33.1 GBq). The findings of diagnostic scans (DS) (2.6–44.4 MBq) were compared to those of corresponding PTS. Results In terms of biodistribution, the PTS identified 131 I‐MIBG activity in one or more patients in the following regions not detected on the DS: nasal mucosa, cerebellum, central brain, adrenals, spleen, kidneys, thyroid, salivary glands, lower halves of the lungs, bladder, bowel, and an incisional scar. Conversely, the DS identified activity in the thorax, heart, kidneys, and bladder each in one patient without being visualized on the PTS. In terms of sensitivity to detect metastatic disease, 210 lesions were seen on the PTS compared to 151 on the DS. The PTS demonstrated sites of disease not evident in the DS in 16 cases. Conclusions The biodistribution of 131 I‐MIBG is different using therapeutic doses as compared to pre‐therapy doses. 131 I‐MIBG imaging following high therapeutic doses often reveals sites of occult metastatic disease that may be clinically relevant. © 2003 Wiley‐Liss, Inc.